Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX) Head-To-Head Comparison

Biodel (NASDAQ: ALBO) and RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Biodel and RegeneRx Biopharmaceuticals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biodel 0 0 6 0 3.00
RegeneRx Biopharmaceuticals 0 0 1 0 3.00

Biodel currently has a consensus price target of $61.67, suggesting a potential upside of 138.19%. RegeneRx Biopharmaceuticals has a consensus price target of $1.50, suggesting a potential upside of 538.30%. Given RegeneRx Biopharmaceuticals’ higher probable upside, analysts clearly believe RegeneRx Biopharmaceuticals is more favorable than Biodel.


This table compares Biodel and RegeneRx Biopharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biodel N/A N/A N/A
RegeneRx Biopharmaceuticals -1,539.62% -23.23% -170.89%

Valuation and Earnings

This table compares Biodel and RegeneRx Biopharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Biodel $11.36 million 20.28 -$4.03 million $2.17 11.93
RegeneRx Biopharmaceuticals $90,000.00 286.67 $220,000.00 ($0.01) -23.50

RegeneRx Biopharmaceuticals has higher revenue, but lower earnings than Biodel. RegeneRx Biopharmaceuticals is trading at a lower price-to-earnings ratio than Biodel, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

27.3% of Biodel shares are owned by institutional investors. Comparatively, 0.1% of RegeneRx Biopharmaceuticals shares are owned by institutional investors. 22.3% of Biodel shares are owned by insiders. Comparatively, 12.1% of RegeneRx Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Biodel has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, RegeneRx Biopharmaceuticals has a beta of -2.7, indicating that its share price is 370% less volatile than the S&P 500.


Biodel beats RegeneRx Biopharmaceuticals on 9 of the 12 factors compared between the two stocks.

Biodel Company Profile

Biodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company’s BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.

RegeneRx Biopharmaceuticals Company Profile

RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The Company has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.

Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with's FREE daily email newsletter.

Leave a Reply